



January 31, 2019

To,

**Manager – Listing Compliance**  
**National Stock Exchange of India Limited,**  
'Exchange Plaza'. C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai - 400 051

**GlaxoSmithKline Consumer Healthcare Ltd.**  
24-25 Floor, One Horizon Center  
Sector 43, DLF Phase 5, Golf Course Road  
Gurugram (Haryana), India - 122002

T +91 124 4336500  
F +91 124 4336600  
E [contact.4.gsk@gsk.com](mailto:contact.4.gsk@gsk.com)  
[www.gsk.com](http://www.gsk.com)

Dear Sir/Ma'am,

**Sub: Submission of Complaints Report as per Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CFD/DIL3/CIR/2017/21 dated March 10, 2017, issued by SEBI and as amended from time to time for the proposed scheme of amalgamation between GlaxoSmithKline Consumer Healthcare Limited ("Transferor Company" or "Company"), Hindustan Unilever Limited ("Transferee Company") and their respective shareholders and creditors.**

Please refer to our application under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the proposed scheme of amalgamation between the Company, the Transferee Company and their respective shareholders and creditors.

Since the draft scheme and related documents were hosted/ uploaded on the website of the NSE on January 10, 2019, please find enclosed herewith the Complaints Report as on January 31, 2019 for your kind perusal in the format specified by the SEBI Circular.

The Complaints Report is also being uploaded on the website of the Company, i.e. [www.gsk-ch.in](http://www.gsk-ch.in), as per the requirement of the SEBI Circular.

We request you to please take note of the same and also provide us with the necessary 'Observation Letter/ No objection' at the earliest.

Thanking you,

For **GlaxoSmithKline Consumer Healthcare Limited**

Shanu Saksena  
(Company Secretary)

**Complaints Report as on January 31, 2019**


**Part A**

Sr. No.	Particulars	Number
1	Number of complaints received directly	NIL
2	Number of complaints forwarded by Stock Exchanges / SEBI	NIL
3	Total Number of complaints/comments received (1+2)	NIL
4	Number of complaints resolved	N.A.
5	Number of complaints pending	N.A.

**Part B**

Sr. No.	Name of complainant	Date of Complaint	Status (Resolved/pending)
Not Applicable			

For **GlaxoSmithKline Consumer Healthcare Limited**

  
\_\_\_\_\_  
Shanu Saksena  
(Company Secretary)